Cartesian Therapeutics enters employment pacts with CSO Jewell ($420K) and CTO Kurtoglu ($440K)

Cartesian Therapeutics, Inc.

Christopher Jewell appointed CSO; annual base salary $420,000, target bonus 40%.
Metin Kurtoglu appointed CTO (was COO); annual base salary $440,000, target bonus 40%.
Severance: 12 months base pay, prorated bonus, and COBRA if terminated without cause or for good reason.
Change-in-control provision: accelerated vesting of time-based equity awards if termination occurs near a change.
Both executives subject to 12-18 month non-compete, non-solicit, and confidentiality covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Jewell

Chief Scientific Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2023-11-13
Filed: April 1, 2024, 7:59 PM ET

As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.

Role change

Metin Kurtoglu

Chief Technology Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2024-03-28
Filed: April 1, 2024, 7:59 PM ET

Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Metin Kurtoglu was appointed as Chief Technology Officer at Cartesian Therapeutics, Inc..

Action: appointed
Role: Chief Technology Officer

Exact text from the filing

Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-24-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.